Recognition, diagnosis, and management of Wilson's disease

Proceedings of the Society for Experimental Biology and Medicine

Volumn 223, Issue 1, 2000, Pages 39-46

  Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; COPPER; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC ACETATE;

AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; COPPER METABOLISM; ENZYME DEFECT; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER DYSFUNCTION; MENKES SYNDROME; NEUROLOGIC DISEASE; NEUROTOXICITY; PROTEINURIA; REVIEW; SKIN TOXICITY; WILSON DISEASE;

EID: 0034109410     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.2000.22305.x     Document Type: Review

References (57)

1. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine 71:139-164, 1992.
2. Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LH Jr., Ed. Major Problems in Internal Medicine. Philadelphia: W.B. Saunders Company, Vol 23, 1984.
3. Schilsky ML. Wilson disease: Genetic basis of copper toxicity and natural history. Seminars in Liver Disease 16:83-95, 1996.
4. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson's disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 5:327-337, 1993.
5. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM, Devoto M, Peppercorn J, Bush AI, Sternlieb I, Pirastu M, Gusella JF, Evgrafov O, Penchaszadeh GK, Honig B, Edelman IS, Soares MB, Scheinberg IH, Gilliam TC. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 5:44-50, 1993.
6. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 197:271-277, 1993.
7. Cox DW. Review: Molecular approaches to inherited liver disease. Focus on Wilson's disease. J Gastroenterol Hepatol 12:5251-5255, 1997.
8. Frommer DJ. Defective biliary excretion of copper in Wilson's disease. Gut 15:125-129, 1974.
9. Gibbs K, Walshe JM. Biliary excretion of copper in Wilson's disease. Lancet 2:538-539, 1980.
10. Iyengar V, Brewer GJ, Dick RD, Owyang C. Studies of cholecystokinin-stimulated biliary secretions reveal a high-molecular-weight, copper-binding substance in normal subjects that is absent in patients with Wilson's disease. J Lab Clin Med 111:267-274, 1988.
11. Fink JK, Hedera P, Brewer GJ. Hepatolenticular degeneration (Wilson's disease). Neurologist 5:171-185, 1999.
12. Kayser B. Ueber einen Fall von angeborener grünlicher Verfärbung der kornea. Klin Mbl Augenheilk 40:22-25, 1902.
13. Fleischer B. Zwei weitere Fälle von grünliche Verfärbung der Kornea. Klin MbI Augenheilk 41:489-491, 1903.
14. Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. Ann Intern Med 99:314-320, 1983.
15. Hill GM, Brewer GJ, Prasad AS, Hydrick CR, Hartmann DE. Treatment of Wilson's disease with zinc: I. Oral zinc therapy regimens. Hepatology 7:522-528, 1987.
16. Hill GM, Brewer GJ, Juni JE, Prasad AS, Dick RD. Treatment of Wilson's disease with zinc: II. Validation of oral 64copper with copper balance. Am J Med Sci 292:344-349, 1986.
17. Brewer GJ, Hill GM, Dick RD, Nostrant TT, Sams JS, Wells JJ, Prasad AS. Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper. J Lab Clin Med 109:526-531, 1987.
18. Brewer GJ, Hill GM, Prasad AS, Dick RD. Treatment of Wilson's disease with zinc: IV. Efficacy monitoring using urine and plasma copper. Proc Soc Exp Biol Med 7:446-455, 1987.
19. Yuzbasiyan-Gurkan V, Brewer GJ, Abrams GD, Main B, Giacherio D. Treatment of Wilson's disease with zinc: V. Changes in serum levels of lipase, amylase, and alkaline phosphatase in Wilson's disease patients. J Lab Clin Med 114:520-526, 1989.
20. Brewer GJ, Yuzbaysian-Gurkan V, Lee D-Y, Appelmann H. The treatment of Wilson's disease with zinc: VI. Initial treatment studies. J Lab Clin Med 114:633-638, 1989.
21. Lee D-Y, Brewer GJ, Wang Y. The treatment of Wilson's disease with zinc: VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model. J Lab Clin Med 114:639-645, 1989.
22. Brewer GJ, Yuzbasiyan-Gurkan V, Dick R. Zinc therapy of Wilson's disease: VIII. Dose-response studies. Trace Elem Exp Med 3:227-234, 1990.
23. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V. The treatment of Wilson's disease with zinc: IX. Response of serum lipids. J Lab Clin Med 118:466-470, 1991.
24. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. The treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 120:380-386, 1992.
25. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr 12:26-30, 1993.
26. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XII. Dose regimen requirements. Am J Med Sci 305:199-202, 1993.
27. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Johnson V, Wang Y. Treatment of Wilson's disease with zinc: XIII. Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 123:849-858, 1994.
28. Brewer GJ, Johnson V, Kaplan J. Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function. J Lab Clin Med 129:649-652, 1997.
29. Brewer GJ, Dick RD, Johnson V, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson's disease with zinc: XV. Long-term follow-up studies. J Lab Clin Med 132:264-278, 1998.
30. Brewer GJ, Brewer LF, Prasad AS. Suppression of irreversibly sickled erythrocytes by zinc therapy in sickle cell anemia. J Lab Clin Med 90:549-554, 1977.
31. Brewer GJ, Schoomaker EB, Leichtman DA, Kruckleberg WC, Brewer LF, Myers N. The uses of pharmacologic doses of zinc in the treatment of sickle cell anemia. In: Brewer GJ, Prasad AS, Eds. Zinc Metabolism: Current Aspects in Health and Disease. New York: Allan R. Liss, Inc., pp241-258, 1977.
32. Prasad AS, Brewer GJ, Schoomaker EB, Rabbini P. Hypocupremia induced by zinc therapy in adults. JAMA 240:2166-2168, 1978.
33. Schouwink G. De hepatocecerebrale degeneratie, met een onderzoek naar de zonkstrofwisseling. MD thesis (with a summary in English, French, and German). University of Amsterdam, 1961.
34. Hoogenraad TU, Koevoet R, De Ruyter Korver EGWM. Oral zinc sulfate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol 18:205-211, 1979.
35. Hoogenraad TU, Van den Hamer CJA, Koevoet R, De Ruyter Korver EGWM. Oral zinc in Wilson's disease. Lancet 2:1262-1263, 1978.
36. Hoogenraad TU, Van Hattum J, Van den Hamer CJA. Management of Wilson's disease with zinc sulfate: Experience in a series of 27 patients. J Neurol Sci 77:137-146, 1987.
37. Hall AC, Young BW, Bremner I. Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat. J Inorg Biochem 11:57-66, 1979.
38. Menard MP, McCormick CC, Cousins RJ. Regulation of intestinal metallothionein biosynthesis in rats by dietary zinc. J Nutr 111:1351-1361, 1981.
39. Oestreicher P, Cousins RJ. Copper and zinc absorption in the rat: Mechanism of mutual antagonism. J Nutr 115:159-166, 1985.
40. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dichloride. Lancet 1:643-647, 1982.
41. Keen CL, Lonnerdal B, Hurley LS. Teratogenic effect of copper deficiency and excess. In: Sorenson JRJ, Ed. Inflammatory diseases and copper. Clifton, NJ: Humana Press, pp109-121, 1982.
42. Walshe JM. Penicillamine: A new oral therapy for Wilson's disease. Am J Med 21:487-495, 1956.
43. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 44:490-493, 1987.
44. Nimni ME, Bavetta LA. Collagen defect induced by penicillamine. Science 150:905-907, 1965.
45. Ronchetti IP, Fornieri C, Contri MB, Quaglino D Jr., Caselgrandi E. Effect of DL-penicillamine on the aorta of growing chickens. Am J Pathol 124:436-447, 1986.
46. Mjolnerod OK, Dommerud SA, Rasmussen K, Gjeruldsen ST. Congenital connective tissue defect probably due to d-penicillamine treatment in pregnancy. Lancet 1:673-675, 1971.
47. Solomon L, Abrams G, Dinner M, Berman L. Neonatal abnormalities associated with d-penicillamine treatment during pregnancy. N Engl J Med 296:54-55, 1977.
48. Mason J. The biochemical pathogenesis of molybdenum-induced copper deficiency syndromes in ruminants: Towards the final chapter. Ir Vet J 43:18-21, 1990.
49. Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem 14:189-207, 1981.
50. Bremner J, Mills CF, Young BW. Copper metabolism in rats given di-or trithiomolybdates. J Inorg Biochem 16:109-119, 1982.
51. Mills CF, El-Gallad TT, Bremner I, Weham G. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 14:163-175, 1981.
52. Gooneratne SR, Howell JM, Gawthorne JM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr 46:469-480, 1981.
53. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, Tanakow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48:42-47, 1991.
54. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkin V, Kluin KJ, Fink JK, Aisen A. Treatment of Wilson's disease with ammonium tetrathiomolybdate: I. Initial therapy in 17 neurologically affected patients. Arch Neurol 51:545-554, 1994.
55. Brewer GJ, Johnson V, Dick RD, Wang Y, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson Disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 53:1017-1025, 1996.
56. Harper PI, Walshe JM. Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br J Haematol 64:851-853, 1986.
57. Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: Clinical presentation and use of prognostic index. Gut 27:1377-1381, 1986.